Cargando…
Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer
Marimastat, low molecular weight heparins and captopril have antiangiogenic activity in vitro and in animal models. We studied the safety and efficacy of the combination of these drugs in patients with advanced cancer. In all, 50 patients were enrolled. Captopril was given orally at a dose of 50 mg...
Autores principales: | Jones, P H, Christodoulos, K, Dobbs, N, Thavasu, P, Balkwill, F, Blann, A D, Caine, G J, Kumar, S, Kakkar, A J, Gompertz, N, Talbot, D C, Ganesan, T S, Harris, A L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364746/ https://www.ncbi.nlm.nih.gov/pubmed/15162145 http://dx.doi.org/10.1038/sj.bjc.6601897 |
Ejemplares similares
-
A phase II trial of marimastat in advanced pancreatic cancer
por: Evans, J D, et al.
Publicado: (2001) -
Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen
por: Primrose, J N, et al.
Publicado: (1999) -
Control of actin filament length by phosphorylation of fragmin-actin complex
Publicado: (1990) -
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
por: Deplanque, G, et al.
Publicado: (2004) -
Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial
por: Bramhall, S R, et al.
Publicado: (2002)